New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer’s Disease

Mounting evidence suggests that diabetes mellitus (DM) is associated with mild cognitive impairment (MCI), vascular dementia and Alzheimer’s disease (AD). Biological, clinical and epidemiological data support a close link between DM and AD. Increasingly, studies have found that several antidiabetic...

Full description

Saved in:
Bibliographic Details
Published in:Metabolic brain disease 2018-08, Vol.33 (4), p.1009-1018
Main Authors: Zhong, Kai Long, Chen, Fang, Hong, Hao, Ke, Xuan, Lv, Yang Ge, Tang, Su Su, Zhu, Yu Bing
Format: Article
Language:English
Subjects:
Alzheimer Disease - drug therapy
Alzheimer Disease - prevention & control
Alzheimer's disease
Antidiabetics
Biochemistry
Biomedical and Life Sciences
Biomedicine
Brain
Cognitive ability
Cognitive Dysfunction - drug therapy
Cognitive Dysfunction - prevention & control
Dementia disorders
Diabetes
Diabetes mellitus
Drugs
Epidemiology
Humans
Hypoglycemic Agents - therapeutic use
Impairment
Inflammation
Memory
Metabolic Diseases
Metabolism
Mitochondria
Neurogenesis
Neurology
Neurosciences
Oncology
Review Article
Vascular dementia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mounting evidence suggests that diabetes mellitus (DM) is associated with mild cognitive impairment (MCI), vascular dementia and Alzheimer’s disease (AD). Biological, clinical and epidemiological data support a close link between DM and AD. Increasingly, studies have found that several antidiabetic agents can promote neurogenesis, and clinically ameliorate cognitive and memory impairments in different clinical settings. Data has shown that these antidiabetic drugs positively affect mitochondrial and synaptic function, neuroinflammation, and brain metabolism. Evidence to date strongly suggests that these antidiabetic drugs could be developed as disease-modifying therapies for MCI and AD in patients with and without diabetes.
ISSN:0885-7490
1573-7365
DOI:10.1007/s11011-018-0227-1